Yun-Hua Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yun-Hua Liu has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Hong Jiang
West China Hospital of Sichuan University
36 shared publications - Lang Chen
Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China
36 shared publications - Hao Kong
State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
35 shared publications - Panpan Ma
Department of Surgical Oncology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
35 shared publications - Xiangji Wu
State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
35 shared publications - Da Wang
Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310001, China
25 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Targeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer
Lipid accumulation is a hallmark of the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment, yet effective strategies to reprogram this lipid-rich niche and restore anti-tumor immunity remain limited. Here, we show that diacylglycerol O-acyltransferase 1 (DGAT1) as a tumor-intrinsic metabolic checkpoint that promotes immune evasion. DGAT1 inhibition rewires tumor lipid metabolism by promoting increased fatty acid uptake and redistribution, thereby depleting extracellular free fatty acids that impair CD8⁺ T cell function. Mechanistically, decreased palmitate availability alleviates endoplasmic reticulum stress, preserves FOXO1 activity, and supports stem-like CD8⁺ T cell differentiation. This competitive lipid remodeling enhances memory potential, restrains terminal exhaustion, and sensitizes PDAC tumors to PD-1 checkpoint blockade in vivo. Together, our findings identify tumor-immune lipid crosstalk as a key barrier to effective immunity in PDAC and establish DGAT1 as a promising therapeutic target to restore T cell function and improve immunotherapy response.
- 25 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTargeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer
Lipid accumulation is a hallmark of the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment, yet effective strategies to reprogram this lipid-rich niche and restore anti-tumor immunity remain limited. Here, we show that diacylglycerol O-acyltransferase 1 (DGAT1) as a tumor-intrinsic metabolic checkpoint that promotes immune evasion. DGAT1 inhibition rewires tumor lipid metabolism by promoting increased fatty acid uptake and redistribution, thereby depleting extracellular free fatty acids that impair CD8⁺ T cell function. Mechanistically, decreased palmitate availability alleviates endoplasmic reticulum stress, preserves FOXO1 activity, and supports stem-like CD8⁺ T cell differentiation. This competitive lipid remodeling enhances memory potential, restrains terminal exhaustion, and sensitizes PDAC tumors to PD-1 checkpoint blockade in vivo. Together, our findings identify tumor-immune lipid crosstalk as a key barrier to effective immunity in PDAC and establish DGAT1 as a promising therapeutic target to restore T cell function and improve immunotherapy response.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s3 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
GO enrichment analysis of genes identified through CUT&Tag data
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s3 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
GO enrichment analysis of genes identified through CUT&Tag data
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S26 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Supplementary Fig. S1 shows representative images of human adjacent normal and PDAC tissues post-surgery, alongside representative images of Masson's trichrome staining for human adjacent normal and PDAC tissues. Supplementary Fig. S2 depicts quality control results of spatial transcriptomics, identifies cell types in human normal pancreas and PDAC tissues, and maps the spatial distribution of major cell types in sections of human adjacent normal and PDAC tissues. Supplementary Fig. S3 displays representative mIHC staining images of human adjacent normal and PDAC tissues. Supplementary Fig. S4 illustrates the mIHC staining and quantification of LYVE1+ macrophages in soft and stiff PDAC tumors. Supplementary Fig. S5 presents the mRNA expression levels of mechanosensitive ion channels and integrins in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S6 illustrates the gating strategy for bone marrow-derived monocytes and macrophages, along with representative monocyte gating in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S7 displays the quality control results of scRNA-seq data derived from human blood and PDAC samples. Supplementary Fig. S8 presents a spatiotemporal analysis of monocytes and macrophages in blood and PDAC tissues from human PDAC patients. Supplementary Fig. S9 illustrates the subcutaneous simulation of PDAC models by injecting stiff or soft hydrogels mixed with KPC cells. Supplementary Fig. S10 presents the protein expression levels of FAK in PYK2-deficient monocytes/macrophages. Supplementary Fig. S11 illustrates the influence of PYK2 on macrophage mechanotransduction in vivo. Supplementary Fig. S12 illustrates the polarization profiles of WT and Ptk2b KO BMDMs under stimulation with LPS, IL-4/IL-13, or conditioned medium. Supplementary Fig. S13 shows PYK2 deficient BMDMs exhibit impaired cell migration. Supplementary Fig. S14 illustrates the impact of PIEZO1 agonists or inhibitors on monocyte differentiation. Supplementary Fig. S15 shows the role of PYK2 as a transcriptional co-regulator in conjunction with AP-1 and/or SP-1. Supplementary Fig. S16 illustrates the effects of PYK2 deficiency in myeloid precursors on the TME and tumor growth in mouse PDAC models. Supplementary Fig. S17 displays the gating strategy and quantitative analysis of myeloid cells and lymphocytes in tissues from mouse PDAC models. Supplementary Fig. S18 presents the gating strategy and quantitative analysis of T cells within a co-culture system of T cells and monocytes/macrophages. Supplementary Fig. S19 illustrates the impact of myeloid-specific PYK2 deficiency on the TME and its enhancement of immunotherapy efficacy in mouse PDAC models. Supplementary Fig. S20 presents the quality control metrics for scRNA-seq data of PDAC tumors from WT + Iso, WT+αPD-1, Ptk2b KO + Iso and Ptk2b KO+αPD-1 groups. Supplementary Fig. S21 depicts the transcriptional profiles of monocytes, macrophages, and fibroblasts across single and combination treatment groups. Supplementary Fig. S22 shows the impact of myeloid-specific Ptk2b deficiency on fibrosis in mouse PDAC tissues. Supplementary Fig. S23 showed the distinct functional profiles of fibroblasts across experimental groups. Supplementary Fig. S24 illustrates the analysis of CD8+ T cells using flow cytometry and mIHC across single and combination treatment groups. Supplementary Fig. S25 shows the palpation-based tumor size measurements for orthotopic PDAC tumors in mice. Supplementary Fig. S26 shows the full Western blot images alongside their corresponding quantitative analyses.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S26 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Supplementary Fig. S1 shows representative images of human adjacent normal and PDAC tissues post-surgery, alongside representative images of Masson's trichrome staining for human adjacent normal and PDAC tissues. Supplementary Fig. S2 depicts quality control results of spatial transcriptomics, identifies cell types in human normal pancreas and PDAC tissues, and maps the spatial distribution of major cell types in sections of human adjacent normal and PDAC tissues. Supplementary Fig. S3 displays representative mIHC staining images of human adjacent normal and PDAC tissues. Supplementary Fig. S4 illustrates the mIHC staining and quantification of LYVE1+ macrophages in soft and stiff PDAC tumors. Supplementary Fig. S5 presents the mRNA expression levels of mechanosensitive ion channels and integrins in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S6 illustrates the gating strategy for bone marrow-derived monocytes and macrophages, along with representative monocyte gating in BM cells cultured on soft, stiff, and TCPS surfaces. Supplementary Fig. S7 displays the quality control results of scRNA-seq data derived from human blood and PDAC samples. Supplementary Fig. S8 presents a spatiotemporal analysis of monocytes and macrophages in blood and PDAC tissues from human PDAC patients. Supplementary Fig. S9 illustrates the subcutaneous simulation of PDAC models by injecting stiff or soft hydrogels mixed with KPC cells. Supplementary Fig. S10 presents the protein expression levels of FAK in PYK2-deficient monocytes/macrophages. Supplementary Fig. S11 illustrates the influence of PYK2 on macrophage mechanotransduction in vivo. Supplementary Fig. S12 illustrates the polarization profiles of WT and Ptk2b KO BMDMs under stimulation with LPS, IL-4/IL-13, or conditioned medium. Supplementary Fig. S13 shows PYK2 deficient BMDMs exhibit impaired cell migration. Supplementary Fig. S14 illustrates the impact of PIEZO1 agonists or inhibitors on monocyte differentiation. Supplementary Fig. S15 shows the role of PYK2 as a transcriptional co-regulator in conjunction with AP-1 and/or SP-1. Supplementary Fig. S16 illustrates the effects of PYK2 deficiency in myeloid precursors on the TME and tumor growth in mouse PDAC models. Supplementary Fig. S17 displays the gating strategy and quantitative analysis of myeloid cells and lymphocytes in tissues from mouse PDAC models. Supplementary Fig. S18 presents the gating strategy and quantitative analysis of T cells within a co-culture system of T cells and monocytes/macrophages. Supplementary Fig. S19 illustrates the impact of myeloid-specific PYK2 deficiency on the TME and its enhancement of immunotherapy efficacy in mouse PDAC models. Supplementary Fig. S20 presents the quality control metrics for scRNA-seq data of PDAC tumors from WT + Iso, WT+αPD-1, Ptk2b KO + Iso and Ptk2b KO+αPD-1 groups. Supplementary Fig. S21 depicts the transcriptional profiles of monocytes, macrophages, and fibroblasts across single and combination treatment groups. Supplementary Fig. S22 shows the impact of myeloid-specific Ptk2b deficiency on fibrosis in mouse PDAC tissues. Supplementary Fig. S23 showed the distinct functional profiles of fibroblasts across experimental groups. Supplementary Fig. S24 illustrates the analysis of CD8+ T cells using flow cytometry and mIHC across single and combination treatment groups. Supplementary Fig. S25 shows the palpation-based tumor size measurements for orthotopic PDAC tumors in mice. Supplementary Fig. S26 shows the full Western blot images alongside their corresponding quantitative analyses.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s8 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s4 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
The GO enrichment analysis results of monocyte/macrophage cell subtype markers
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s4 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
The GO enrichment analysis results of monocyte/macrophage cell subtype markers
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s1 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
The patient information of ST samples
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s1 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
The patient information of ST samples
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s2 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Gene markers, DEGs and GSEA analysis
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s2 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Gene markers, DEGs and GSEA analysis
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s5 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s5 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s5 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s5 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s6 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s6 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s6 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s6 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table s7 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s7 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable s7 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer
Table s7 from The Immunomechanical Checkpoint PYK2 Governs Monocyte-to-Macrophage Differentiation in Pancreatic Cancer